ClinicalTrials.Veeva

Menu

Blueberries, Inflammation, Motivation, and Physical Activity

Hebrew SeniorLife logo

Hebrew SeniorLife

Status

Completed

Conditions

Depressive Symptoms

Treatments

Other: Freeze-dried Blueberry Powder
Other: Placebo Powder

Study type

Interventional

Funder types

Other

Identifiers

NCT05735587
Pro00064749

Details and patient eligibility

About

The purpose of this study is to determine the feasibility and preliminary efficacy of daily supplementation of freeze-dried blueberry to modulate inflammation-driven lack of motivation in 40 sedentary, older adults with depressive symptoms.

Full description

The investigators will conduct a 14 week, single-site, randomized, double-blind, parallel pilot study in 40 sedentary, older adults with depressive symptoms. Participants will first enter a 2-week washout period where they will avoid consumption of foods high in fiber and anthocyanins (e.g., blueberries) and will also be wearing an activity monitor. Participants will then be randomized to consume either 48 g of freeze-dried blueberry powder (~600 mg of anthocyanins and ~8 g of fiber) or 48 g of a nutritionally matched placebo powder (devoid of anthocyanins and fiber) each day for a total of 12 weeks.

At baseline, participants will be undergo assessments for mood/well-being, relevant symptoms, motivation to engage in physical activity, and provide a blood sample for the evaluation of inflammatory biomarkers. For the entire duration of the study, participants will continue to wear the activity monitor. After 4, 6, 8 and 12 weeks of consuming the powder there will be study visits that assess mood/well-being, relevant symptoms, motivation to engage in physical activity and compliance with the intervention. Additionally, a blood sample for the evaluation of inflammatory makers will be taken after 6 and 12 weeks of the intervention.

Enrollment

33 patients

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women aged ≥65 years
  • Self-reporting ≥ 8 hours of sitting per/day (e.g., sedentary behavior)
  • Depressive symptoms (defined as ≥4 and <16 points on the center for epidemiological studies depression-scale)

Exclusion criteria

  • Unwilling to follow the study protocol
  • A median daily step count >7,500 steps per day (as measured by the ActiGraph), or per discretion of the PI
  • Cognitive impairment (defined as Montreal Cognitive Assessment, MoCA <22 points)
  • Self-reporting a history of inflammatory bowel disease/syndrome, major depression, bipolar, schizophrenia, or other psychotic disorders, or per discretion of the PI
  • Self-reporting type 1 or type 2 diabetes
  • Allergic to intervention or control products
  • Recent use (within the last 3 months) of antibiotics, or per discretion of the PI
  • Recent use (within the last 3 months) of pro-biotics, or per discretion of the PI
  • Current substance use disorder (Drug Abuse Screening Test, DAST-10>2 points)
  • Current alcohol use disorder (Alcohol Use Disorders Identification Test - Consumption, AUDIT-C≥4 points)
  • Unstable anti-depressant use (e.g., change in medication within last 3-6 months), or per discretion of the PI
  • Current homicidal or suicidal ideation (assessed via the P4 Suicidality Screener)
  • Current psychosis (via the Psychosis and Hallucinations Questionnaire, PHQ>12 points)
  • Manic symptoms (assessed by the Mood Disorder Questionnaire, MDQ >5 points)

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

33 participants in 2 patient groups, including a placebo group

Freeze-dried Blueberry Powder
Experimental group
Description:
Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
Treatment:
Other: Freeze-dried Blueberry Powder
Placebo Powder
Placebo Comparator group
Description:
Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
Treatment:
Other: Placebo Powder

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Alex Wolfe, MS; Katie Baldyga, BA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems